A model for the epigenetic switch linking inflammation to cell transformation: deterministic and stochastic approaches.
Recently, a molecular pathway linking inflammation to cell transformation has been discovered. This molecular pathway rests on a positive inflammatory feedback loop between NF-κB, Lin28, Let-7 microRNA and IL6, which leads to an epigenetic switch allowing cell transformation. A transient activation of an inflammatory signal, mediated by the oncoprotein Src, activates NF-κB, which elicits the expression of Lin28. Lin28 decreases the expression of Let-7 microRNA, which results in higher level of IL6 than achieved directly by NF-κB. In turn, IL6 can promote NF-κB activation. Finally, IL6 also elicits the synthesis of STAT3, which is a crucial activator for cell transformation. Here, we propose a computational model to account for the dynamical behavior of this positive inflammatory feedback loop. By means of a deterministic model, we show that an irreversible bistable switch between a transformed and a non-transformed state of the cell is at the core of the dynamical behavior of the positive feedback loop linking inflammation to cell transformation. The model indicates that inhibitors (tumor suppressors) or activators (oncogenes) of this positive feedback loop regulate the occurrence of the epigenetic switch by modulating the threshold of inflammatory signal (Src) needed to promote cell transformation. Both stochastic simulations and deterministic simulations of a heterogeneous cell population suggest that random fluctuations (due to molecular noise or cell-to-cell variability) are able to trigger cell transformation. Moreover, the model predicts that oncogenes/tumor suppressors respectively decrease/increase the robustness of the non-transformed state of the cell towards random fluctuations. Finally, the model accounts for the potential effect of competing endogenous RNAs, ceRNAs, on the dynamics of the epigenetic switch. Depending on their microRNA targets, the model predicts that ceRNAs could act as oncogenes or tumor suppressors by regulating the occurrence of cell transformation.
Oxford Centre for Integrative Systems Biology, Department of Biochemistry, University of Oxford, Oxford, United Kingdom ; de Duve Institute, Université Catholique de Louvain (UCL), Brussels, Belgium.
Claude
C
Gérard
Faculté des Sciences, Université Libre de Bruxelles (ULB), Campus Plaine, Brussels, Belgium.
Didier
D
Gonze
de Duve Institute, Université Catholique de Louvain (UCL), Brussels, Belgium.
Frédéric
F
Lemaigre
Oxford Centre for Integrative Systems Biology, Department of Biochemistry, University of Oxford, Oxford, United Kingdom.
Béla
B
Novák
D002471:Cell Transformation, Neoplastic; D003198:Computer Simulation; D044127:Epigenesis, Genetic; D016147:Genes, Tumor Suppressor; D006801:Humans; D007249:Inflammation; D007700:Kinetics; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D008954:Models, Biological; D016328:NF-kappa B / Q000378:metabolism; D009857:Oncogenes; D051059:PTEN Phosphohydrolase / Q000378:metabolism; D016601:RNA-Binding Proteins / Q000378:metabolism; D050796:STAT3 Transcription Factor / Q000378:metabolism; D013269:Stochastic Processes
C000715187:Lin28A protein, human; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D016328:NF-kappa B; D016601:RNA-Binding Proteins; D050796:STAT3 Transcription Factor; C494086:STAT3 protein, human; C487931:mirnlet7 microRNA, human; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human